Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program

Emerging evidence has illustrated the importance of epigenomic reprogramming in cancer, with altered post-translational modifications of histones contributing to pathogenesis. However, the contributions of histone modifiers to breast cancer progression are unclear, and how these processes vary betwe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirukawa, Alison, Smith, Harvey W., Zuo, Dongmei, Dufour, Catherine R., Savage, Paul, Bertos, Nicholas, Johnson, Radia M., Bui, Tung, Bourque, Guillaume, Basik, Mark, Giguère, Vincent, Park, Morag, Muller, William J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026192/
https://www.ncbi.nlm.nih.gov/pubmed/29959321
http://dx.doi.org/10.1038/s41467-018-04864-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026192/
https://www.ncbi.nlm.nih.gov/pubmed/29959321
http://dx.doi.org/10.1038/s41467-018-04864-8

Ejemplares similares